Urolog. pro Praxi, 2005; 5: 189-192

OVERACTIVE BLADDER - PRESENT LOOK AT ETIOPATHOGENESIS, DIAGNOSIS AND PHARMACOTHERAPY

MUDr. Jan Krhut
Urologické oddělení FNsP Ostrava

The term overactive bladder indicates a complex of symptoms – frequency, urgency and/or urge incontinence. Currently, according to the recommendation of International Continence Society this term replaces previously used expression urge incontinence. Overactive bladder belongs among the most common problems of our population. Lot of attention is paid to this problem recently from many points of view. The aim of this targeted article is to present an overview on new findings from pathophysiology, diagnosis and pharmacotherapy of overactive bladder during past three years.

Keywords: Key words: muscarinic receptors, autonomous bladder theory, anticholinergics, urodynamic evaluation.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krhut J. OVERACTIVE BLADDER - PRESENT LOOK AT ETIOPATHOGENESIS, DIAGNOSIS AND PHARMACOTHERAPY. Urol. praxi. 2005;6(5):189-192.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998; 81(6): 801. Go to original source... Go to PubMed...
    2. Andersson KE, Pehrson R. CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention. Drugs 2003; 63(23): 2595. Go to original source... Go to PubMed...
    3. Appell RA: Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. Curr Urol Rep. 2003; 4(5): 343. Go to original source... Go to PubMed...
    4. Bemelmans BL, Kiemeney LA, Debruyne FM. Low-dose oxybutynin for the treatment of urge incontinence: good efficacy and few side effects. Eur Urol. 2000; 37(6): 709. Go to original source... Go to PubMed...
    5. Brading AF. A myogenic basis for the overactive bladder. Urology. 1997; 50(6A Suppl): 57. Go to original source... Go to PubMed...
    6. Cardozo L, Lisec M, Millard R, van Vierssen Trip O, Kuzmin I, Drogendijk TE, Huang M, Ridder AM. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 2004; 172: 1919. Go to original source... Go to PubMed...
    7. Colli E, Artibani W, Goka J, Parazzini F, Wein AJ. Are urodynamic tests useful tools for the initial conservative management of non-neurogenic urinary incontinence? A review of the literature. Eur Urol 2003; 43(1): 63. Go to original source... Go to PubMed...
    8. Davila GW, Daugherty CA, Sanders SW; Transdermal Oxybutynin Study Group: A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001; 166(1): 140. Go to original source... Go to PubMed...
    9. Digesu GA, Khullar V, Cardozo L, Salvatore S. Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn 2003; 22(2): 105. Go to original source... Go to PubMed...
    10. Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW, Transdermal Oxybutynin Study Group: Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003; 62(2): 237. Go to original source... Go to PubMed...
    11. Gillespie JI. The autonomous bladder: a view of the origin of bladder overactivity and sensory urge. BJU Int 2004; 93(4): 478. Go to original source... Go to PubMed...
    12. de Groat WC. Anatomy of the central neural pathways controlling the lower urinary tract. Eur Urol 1998; 34 Suppl 1:2. Go to original source... Go to PubMed...
    13. Hampel C, Gillitzer R, Pahernik S, Hohenfellner M, Thüroff JW: Epidemiology and etiology of overactive bladder. Urologe A 2003; 42: 776. Go to original source... Go to PubMed...
    14. Hampel C, Gillitzer R, Pahernik S, Melchior SW, Thüroff JW. Veränderungen des Rezeptorprofils der alternden Blase. Urologe A 2004; 43 (5): 535. Go to original source... Go to PubMed...
    15. Hampel C, Thüroff JW. Pharmakologie des Harntraktes. In: Palmtag H, Goepel M, Heidler H (Hrsg) Urodynamik. Springer, Berlin Heidelberg New York Tokio, 2004: 17-33. Go to original source...
    16. Hawthorn MH, Chapple CR, Cock M, Chess-Williams R. Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br J Pharmacol 2000; 129 (3): 416. Go to original source... Go to PubMed...
    17. Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A. YM-905 Study Group: Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93(3): 303. Go to original source... Go to PubMed...
    18. Chess-Williams R. Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton Autacoid Pharmacol. 2002; 22(3): 133. Go to original source... Go to PubMed...
    19. Ikeda K, Kobayashi S, Suzuki M, Miyata K, Takeuchi M, Yamada T, Honda K. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol. 2002; 366(2): 97. Go to original source... Go to PubMed...
    20. McGrother CW, Donaldson MM, Shaw C, Matthews RJ, Hayward TA, Dallosso HM, Jagger C, Clarke M, Castleden CM. MRC Incontinence Study Team.Storage symptoms of the bladder: prevalence, incidence and need for services in the UK. BJU Int 2004; 93(6): 763. Go to original source... Go to PubMed...
    21. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760. Go to original source... Go to PubMed...
    22. Moorthy P, Lapitan MC, Quek PL, Lim PH. Prevalence of overactive bladder in Asian men: an epidemiological survey. BJU Int 2004; 93(4): 528. Go to original source... Go to PubMed...
    23. Nelson CP, Gupta P, Napier CM, Nahorski SR, Challiss RA. Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland. J Pharmacol Exp Ther. 2004; 310(3): 1255. Go to original source... Go to PubMed...
    24. Scarpero HM, Dmochowski RR. Muscarinic receptors: what we know. Curr Urol Rep 2003; 4(6): 421. Go to original source... Go to PubMed...
    25. Siami P, Seidman LS, Lama D. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Clin Ther 2002; 24(4): 616. Go to original source... Go to PubMed...
    26. Uchiyama T, Chess-Williams R. Muscarinic receptor subtypes of the bladder and gastrointestinal tract. J Smooth Muscle Res. 2004; 40 (6): 237. Go to original source... Go to PubMed...
    27. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A; Tolterodine Study Group: Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57(3): 414. Go to original source... Go to PubMed...
    28. Viktrup L, Summers KH, Dennett SL. Clinical practice guidelines for the initial management of urinary incontinence in women: a European-focused review. BJU Int 2004; 94 Suppl 1: 14. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.